{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:36:35Z","timestamp":1793414195461,"version":"4.5.0"},"reference-count":60,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>In the management of neurological diseases, the identification and quantification of axonal damage could allow for the improvement of diagnostic accuracy and prognostic assessment. Neurofilament light chain (NfL) is a neuronal cytoplasmic protein highly expressed in large calibre myelinated axons. Its levels increase in cerebrospinal fluid (CSF) and blood proportionally to the degree of axonal damage in a variety of neurological disorders, including inflammatory, neurodegenerative, traumatic and cerebrovascular diseases. New immunoassays able to detect biomarkers at ultralow levels have allowed for the measurement of NfL in blood, thus making it possible to easily and repeatedly measure NfL for monitoring diseases\u2019 courses. Evidence that both CSF and blood NfL may serve as diagnostic, prognostic and monitoring biomarkers in neurological diseases is progressively increasing, and NfL is one of the most promising biomarkers to be used in clinical and research setting in the next future. Here we review the most important results on CSF and blood NfL and we discuss its potential applications and future directions.<\/jats:p>","DOI":"10.1136\/jnnp-2018-320106","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T21:21:55Z","timestamp":1554844915000},"page":"870-881","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1274,"title":["Neurofilament light chain as a biomarker in neurological disorders"],"prefix":"10.1136","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3967-8954","authenticated-orcid":false,"given":"Lorenzo","family":"Gaetani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilla","family":"Parnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"key":"2020050722344753000_90.8.870.1","doi-asserted-by":"crossref","unstructured":"Olsson B , Portelius E , Cullen NC , et al . Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol 2018:1\u20138.doi:10.1001\/jamaneurol.2018.3746","DOI":"10.1001\/jamaneurol.2018.3746"},{"key":"2020050722344753000_90.8.870.2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol"},{"key":"2020050722344753000_90.8.870.3","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1212\/WNL.0000000000004029","article-title":"Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease","volume":"88","author":"Poesen","year":"2017","journal-title":"Neurology"},{"key":"2020050722344753000_90.8.870.4","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513482374"},{"key":"2020050722344753000_90.8.870.5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-307454"},{"key":"2020050722344753000_90.8.870.6","doi-asserted-by":"crossref","unstructured":"S M , A F , S M , et al . Serum neurofilament light chain in NMOSD and related disorders: comparison according to aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status. Mult Scler J Exp Transl Clin 2017;3:2055217317743098.doi:10.1177\/2055217317743098","DOI":"10.1177\/2055217317743098"},{"key":"2020050722344753000_90.8.870.7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol"},{"key":"2020050722344753000_90.8.870.8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuint.2017.05.010","article-title":"Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease","volume":"108","author":"Lista","year":"2017","journal-title":"Neurochem Int"},{"key":"2020050722344753000_90.8.870.9","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606540"},{"key":"2020050722344753000_90.8.870.10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004088"},{"key":"2020050722344753000_90.8.870.11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","article-title":"Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia","volume":"87","author":"Rohrer","year":"2016","journal-title":"Neurology"},{"key":"2020050722344753000_90.8.870.12","first-page":"1","article-title":"Association of cerebrospinal fluid neurofilament light protein with risk of mild cognitive impairment among individuals without cognitive impairment","volume":"55905","author":"Kern","year":"2018","journal-title":"JAMA Neurol"},{"key":"2020050722344753000_90.8.870.13","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2006.107326"},{"key":"2020050722344753000_90.8.870.14","first-page":"1","article-title":"Cerebrospinal fluid in the differential diagnosis of Alzheimer\u2019s disease: Clinical utility of an extended panel of biomarkers in a specialist cognitive clinic","volume":"10","author":"Paterson","year":"2018","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"2020050722344753000_90.8.870.15","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1212\/WNL.0000000000003688","article-title":"Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias","volume":"88","author":"Steinacker","year":"2017","journal-title":"Neurology"},{"key":"2020050722344753000_90.8.870.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-016-0001-8"},{"key":"2020050722344753000_90.8.870.17","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317793"},{"key":"2020050722344753000_90.8.870.18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-017-0331-1","article-title":"The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias","volume":"10","author":"Abu-Rumeileh","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"2020050722344753000_90.8.870.19","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1212\/WNL.0000000000004761","article-title":"Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis","volume":"90","author":"Feneberg","year":"2018","journal-title":"Neurology"},{"key":"2020050722344753000_90.8.870.20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001642"},{"key":"2020050722344753000_90.8.870.21","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318704"},{"key":"2020050722344753000_90.8.870.22","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24552"},{"key":"2020050722344753000_90.8.870.23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ana.25276","article-title":"Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion","volume":"84","author":"Benatar","year":"2018","journal-title":"Ann Neurol"},{"key":"2020050722344753000_90.8.870.24","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1007\/s00415-015-7904-3","article-title":"Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis","volume":"262","author":"Paterson","year":"2015","journal-title":"J Neurol"},{"key":"2020050722344753000_90.8.870.25","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamaneurol.2015.1449","article-title":"Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease","volume":"72","author":"B\u00e4ckstr\u00f6m","year":"2015","journal-title":"JAMA Neurol"},{"key":"2020050722344753000_90.8.870.26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2015.00091","article-title":"CSF neurofilament light chain but not Flt3 ligand discriminates Parkinsonian disorders","volume":"6","author":"Herbert","year":"2015","journal-title":"Front Neurol"},{"key":"2020050722344753000_90.8.870.27","doi-asserted-by":"crossref","unstructured":"Hansson O , Janelidze S , Hall S , et al . Blood-based NFL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 2017;88.doi:10.1212\/WNL.0000000000003680","DOI":"10.1212\/WNL.0000000000003680"},{"key":"2020050722344753000_90.8.870.28","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.1654"},{"key":"2020050722344753000_90.8.870.29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001015"},{"key":"2020050722344753000_90.8.870.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-016-0001-8"},{"key":"2020050722344753000_90.8.870.31","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.9.1277"},{"key":"2020050722344753000_90.8.870.32","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00167-014-3066-6","article-title":"Monitoring concussion in a knocked-out boxer by CSF biomarker analysis","volume":"23","author":"Neselius","year":"2015","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"2020050722344753000_90.8.870.33","doi-asserted-by":"publisher","DOI":"10.1136\/bjsm.2007.037143"},{"key":"2020050722344753000_90.8.870.34","doi-asserted-by":"publisher","DOI":"10.1089\/089771503322385782"},{"key":"2020050722344753000_90.8.870.35","doi-asserted-by":"crossref","unstructured":"Korley FK , Yue JK , Wilson D , et al . Performance evaluation of a multiplex assay for simultaneous detection of four clinically relevant TBI biomarkers. J Neurotrauma 2018:1\u201325.","DOI":"10.1089\/neu.2017.5623"},{"key":"2020050722344753000_90.8.870.36","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.0000000000003653","article-title":"Serum neurofilament is associated with progression of brain atrophy and disability in early MS","volume":"88","author":"Kuhle","year":"2017","journal-title":"Neurology"},{"key":"2020050722344753000_90.8.870.37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.msard.2016.12.001","article-title":"No evidence of disease activity (NEDA) in MS should include CSF biology - Towards a 'Disease-Free Status Score'","volume":"11","author":"Bonnan","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"2020050722344753000_90.8.870.38","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510364992"},{"key":"2020050722344753000_90.8.870.39","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/brain\/awy021","article-title":"Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome","volume":"141","author":"Matute-Blanch","year":"2018","journal-title":"Brain"},{"key":"2020050722344753000_90.8.870.40","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309690"},{"key":"2020050722344753000_90.8.870.41","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/WNL.0000000000003085","article-title":"Neurofilament light chain level is a weak risk factor for the development of MS","volume":"87","author":"Arrambide","year":"2016","journal-title":"Neurology"},{"key":"2020050722344753000_90.8.870.42","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"key":"2020050722344753000_90.8.870.43","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515574148"},{"key":"2020050722344753000_90.8.870.44","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509359725"},{"key":"2020050722344753000_90.8.870.45","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Valle R , Heslegrave A , Foiani MS , et al . Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease. Alzheimers Res Ther 2018;10.doi:10.1186\/s13195-018-0439-y","DOI":"10.1186\/s13195-018-0439-y"},{"key":"2020050722344753000_90.8.870.46","doi-asserted-by":"crossref","first-page":"e1231","DOI":"10.1212\/WNL.0000000000005261","article-title":"Clinical value of neurofilament and phospho-tau\/tau ratio in the frontotemporal dementia spectrum","volume":"90","author":"Meeter","year":"2018","journal-title":"Neurology"},{"key":"2020050722344753000_90.8.870.47","first-page":"757","article-title":"Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia","volume":"1","author":"Mattsson","year":"2008","journal-title":"Mol Med Rep"},{"key":"2020050722344753000_90.8.870.48","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jamaneurol.2016.5398","article-title":"Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: Neurofilament light chain levels in definite subtypes of disease","volume":"74","author":"Gaiani","year":"2017","journal-title":"JAMA Neurol"},{"key":"2020050722344753000_90.8.870.49","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/21678421.2016.1241279","article-title":"Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100b, in the course of amyotrophic lateral sclerosis: data from the German MND-net","volume":"18","author":"Steinacker","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2020050722344753000_90.8.870.50","doi-asserted-by":"crossref","unstructured":"Gille B , De Schaepdryver M , Goossens J , et al . Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 2018;377.doi:10.1111\/nan.12511","DOI":"10.1111\/nan.12511"},{"key":"2020050722344753000_90.8.870.51","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/21678421.2017.1281962","article-title":"Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival","volume":"18","author":"Skillb\u00e4ck","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2020050722344753000_90.8.870.52","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/acn3.290","article-title":"Plasma neurofilament light chain predicts progression in progressive supranuclear palsy","volume":"3","author":"Rojas","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"2020050722344753000_90.8.870.53","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1212\/WNL.0000000000004859","article-title":"CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP","volume":"90","author":"Rojas","year":"2018","journal-title":"Neurology"},{"key":"2020050722344753000_90.8.870.54","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1089\/neu.2016.4496","article-title":"Serum neurofilament light protein as a marker for diffuse axonal injury: results from a case series study","volume":"34","author":"Ljungqvist","year":"2017","journal-title":"J Neurotrauma"},{"key":"2020050722344753000_90.8.870.55","doi-asserted-by":"crossref","first-page":"e1780","DOI":"10.1212\/WNL.0000000000005518","article-title":"Neurofilament light and tau as blood biomarkers for sports-related concussion","volume":"90","author":"Shahim","year":"2018","journal-title":"Neurology"},{"key":"2020050722344753000_90.8.870.56","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22247"},{"key":"2020050722344753000_90.8.870.57","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12151"},{"key":"2020050722344753000_90.8.870.58","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513490544"},{"key":"2020050722344753000_90.8.870.59","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002832"},{"key":"2020050722344753000_90.8.870.60","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/1352458516639384","article-title":"Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis","volume":"23","author":"Novakova","year":"2017","journal-title":"Mult Scler"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2018-320106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T04:46:41Z","timestamp":1601095601000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2018-320106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,9]]},"references-count":60,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,7,11]]},"published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1136\/jnnp-2018-320106"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2018-320106","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,9]]}}}